Neervannan Seshadri 4

What Happened
Neervannan Seshadri, Chief Operating Officer of Tarsus Pharmaceuticals (TARS), reported a sale of 2,989 shares on March 20, 2026. The shares were sold at $66.75 per share for a total proceeds of $199,516. The Form 4 lists the transaction as an open-market or private sale and indicates the sale was effected under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-03-20; Report filed: 2026-03-24.
• Price and amount: 2,989 shares at $66.75 each; total value $199,516.
• Shares owned after transaction: not specified in the information provided in this summary.
• Footnote: Sale was executed automatically under a Rule 10b5-1 trading plan adopted by the reporting person on November 13, 2025.
• Footnote: A holding balance disclosed in the filing relates to the reporting person’s daughter (same household); the reporting person disclaims beneficial ownership of those shares.
• Timeliness: filing date and transaction date are shown above; check the official filing for whether the Form 4 was timely per SEC two-business-day rule.

Context
Sales executed under 10b5-1 plans are pre-arranged and often represent routine, automated disposition rather than real-time trading decisions. The daughter’s holdings are disclaimed by the reporting person, so those shares are not counted as his beneficial ownership in this report. For further detail or to confirm share balances, consult the full SEC Form 4 filing (Accession: 0001827584-26-000011).